Clinical Trial Update: PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports Phase 1/Phase 2 results for the combination of PTK 787 and imatinib (Gleevec) in patients with acute myeloid leukemia, primar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia
• Myelofibrosis

Drugs mentioned

• Gleevec (Imatinib)
• PTK 787 (vatalanib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myelogenous Leukemia, Agnogenic Myeloid Metaplasia | Phase 1, Phase 2 | Status: COMPLETED